コンテンツメニュー

Matsumoto Hiroaki

Affiliate Master Yamaguchi University

Publish Date (<span class="translation_missing" title="translation missing: en.view.desc">Desc</span>)
Androgen receptor (AR)-signaling plays an important role in promoting tumor cell survival and the development of castration-resistant prostate cancer (CRPC). Androgen deprivation therapy is the basic therapeutic strategy for AR signaling blockade, but that effects wonʼt last long and most of metastatic prostate cancer show castration resistance. Recently, new agents, AR Axis Targeted agents (ARAT), have been developed. We have been developing our bench-to-bedside translational research to elucidate the mechanisms of drug resistance in prostate cancer. This review describes our investigational results and recent advances in CRPC with ARAT treatment strategy.
Creators : Matsumoto Hiroaki Matsuyama Hideyasu Publishers : Yamaguchi University School of Medicine
西日本泌尿器科 Volume 75 Issue 4 pp. 170 - 177
published_at 2013-04-20
Creators : Matsumoto Hiroaki Matsuyama Hideyasu Publishers : 日本泌尿器科学会西日本総会
The Nishinihon journal of urology Volume 75 Issue 6 pp. 311 - 317
published_at 2013-06
Creators : 原 貴彦 小林 圭太 西嶋 淳 川井 禎久 松本 洋明 長尾 一公 坂野 滋 松山 豪泰 Publishers : 日本泌尿器科学会西日本連合地方会
Japanese journal of urological surgery Volume 25 Issue 8 pp. 1693 - 1695
published_at 2012-08-15
Creators : Matsumoto Hiroaki Nishijima Jun Miyachika Yoshihiro Kawai Yoshihisa Hara Takahiko Sakano Shigeru 沖本 智明 Matsunaga Naofumi Matsunga Hideyasu Publishers : 医学図書出版
西日本泌尿器科 Volume 74 Issue 9 pp. 492 - 496
published_at 2012-09
Creators : 川井 禎久 西嶋 淳 山本 義明 松本 洋明 長尾 一公 原 貴彦 坂野 滋 松山 豪泰 Publishers : 日本泌尿器科学会西日本総会